Eli Lilly expands partnership with Gate Bioscience, committing up to $870 million
Eli Lilly announced an expanded multi‑year licensing agreement with Gate Bioscience, granting Lilly exclusive worldwide rights to develop and commercialize any drugs emerging from the collaboration. The deal includes an undisclosed upfront payment and milestone payments that could total up to $870 million, plus tiered royalties on future sales. The partnership will initially focus on a single new molecular‑gate target, with an option to add a second later. Lilly will lead later‑stage development and commercialization while Gate handles early discovery.
Why it matters
The company expects the deal to broaden its early‑stage pipeline and could generate future revenue streams, though payments are contingent on milestones. Analysts note that the announcement lifted Lilly’s share price, indicating market optimism about the new modality.
Key facts
- 1Lilly will pay an undisclosed upfront amount and milestone payments that could total up to $870 million. finance.yahoo.com
- 2Lilly receives exclusive global development and commercial rights to any drugs created under the partnership. finance.yahoo.com
- 3The expanded agreement initially targets a single new protein and includes an option for a second target later. finance.yahoo.com
- 4Lilly’s shares rose 1.6% to $1,161.50 after the announcement. finance.yahoo.com
- 5Lilly’s shares were up 3.6% to $1,200.23 on October 7, 2026. gurufocus.com
Open questions
- Two sources report different share price reactions: $1,161.50 (up 1.6%) and $1,200.23 (up 3.6%).
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.